Either trial will drive viral load to zero (or near zero) as Brilacidin is an antiviral (meaning it kills the virus) whereas most, if not all, of the other current drugs only attack the symptoms and prevent the virus from replicating as opposed to killing the virus.
Pretty sure the thinking was that those in the know knew Brilacidin could and would cure those with the most severe symptoms and thus everyone would also come to the conclusion it would also cure those with milder symptoms.
IMO this shows supreme confidence in Brilacidin and why longs feel the trial is going to be an overwhelming success (especially when we know that the SOC cannot reduce the viral load or work against anything but mild symptoms.
White Bronco, you and Bizzy and Pete raise good points. Kind of makes my head spin. The need for anti-virals remains, and that train will keep on track, let's hope B is among the proven leaders. My hunch, as I am typing, is that newly revised monoclonal anti-bodies will also be joining the frey.
Market Data 
Markets 
AI
